MonoSol seeks partners after reacquiring Zuplenz for cancer; microneedles best for H1N1 vaccine delivery;

> MonoSol Rx, which specializes in developing thin-film versions of existing drugs, has reacquired the commercial rights to Zuplenz from Strativa Pharmaceuticals and seeking partners to market the oral soluble film prescribed for the treatment of emetogenic cancer chemotherapy and radiotherapy-induced nausea and vomiting. MonoSol release

> A vaccine delivered to the skin using a microneedle patch gives better protection against the H1N1 influenza virus than a vaccine delivered through subcutaneous or intramuscular injection, say researchers from Emory University and Georgia Tech. Release

> University of South Florida researchers have used rat Sertoli cells to successfully deliver therapeutics deep into the lung. Sertoli cells are present in the testes and are also called "nurse" or "mother" cells because they nurture developing sperm cells. Release

> Medtronic warns of battery issue with drug-delivery pump. Item

> India's Venus Remedies has launched its Achnil pain-killer, an injection formulation that will "fill in the gap of long-standing demand for better pain management therapies, especially for the aged population," according to the company. Story

> Drug delivery patent application of the week: Drug Delivery Using Fine Fiber Encapsulation Application

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.